Bermekimab
Bermekimab[1] (MABp1, trade name Xilonix) is a human monoclonal antibody of IgG1k isotype targeting Interleukin 1 alpha (IL1A).[2] As of March 2017, bermekimab is in phase III clinical trials as an immunotherapy for colorectal cancer[3] and as of September 2018 in phase II clinical trials for the treatment of atopic dermatitis.[4]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | IL1A |
| Clinical data | |
| Trade names | Xilonix |
| Other names | MABp1 |
| Routes of administration | intravenous |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6464H10024N1736O2000S44 |
| Molar mass | 145468.09 g·mol−1 |
Bermekimab is being developed by XBiotech Inc.[5]
References
- Statement On A Nonproprietary Name Adopted By The USAN Council - Bermekimab, American Medical Association.
- Hong DS, Hui D, Bruera E, Janku F, Naing A, Falchook GS, et al. (May 2014). "MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study". The Lancet. Oncology. 15 (6): 656–66. doi:10.1016/S1470-2045(14)70155-X. PMID 24746841.
- Clinical trial number NCT01767857 for "A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer (XCITE)" at ClinicalTrials.gov
- Clinical trial number NCT03496974 for "A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis" at ClinicalTrials.gov
- "Xilonix True Human monoclonal antibody by Xbiotech oncology". www.xbiotech.com. XBiotech. Retrieved 3 March 2017.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.